Supernus Pharmaceuticals Surprises with Strong Earnings
Quarterly Earnings and Revenue Exceed Expectations
Supernus Pharmaceuticals (SUPN) recently reported quarterly earnings of $1.06 per share, significantly exceeding the Zacks Consensus Estimate of $0.39 per share. This is a notable turnaround from a loss of $0.29 per share reported a year ago. These results have been adjusted for non-recurring items.
This achievement represents an impressive earnings surprise of 171.79%. In the previous quarter, expectations were for earnings of $0.37 per share, but the company only managed to deliver $0.36, resulting in a negative surprise of 2.70%.
Over the past year, Supernus has outperformed consensus EPS estimates only once.
Operating in the Zacks Medical – Generic Drugs sector, Supernus generated revenues of $175.69 million for the quarter ending September 2024, surpassing the Zacks Consensus Estimate by 13.30%. In comparison, revenues from the same period last year were $153.88 million. The company has topped revenue expectations in three out of the last four quarters.
The future movement of the stock’s price will likely depend on management’s insights during the upcoming earnings call.
Year-to-date, Supernus shares have risen approximately 17.4%, while the S&P 500 has grown by 20.1%.
Future Outlook for Supernus
Despite underperforming the market this year, investors are left wondering about the future of Supernus stock.
While specific predictions are challenging, the company’s earnings outlook serves as a helpful tool for investors. This includes current consensus earnings expectations for coming quarters and any recent changes to these expectations.
Research indicates a strong link between stock movements and trends in earnings estimate revisions. Investors can monitor these revisions independently or utilize resources like the Zacks Rank, which effectively highlights earnings estimate trends.
Currently, the trend for Supernus’s earnings estimates is unfavorable. Although this can shift following the recent earnings report, the current standing reflects a Zacks Rank of #4 (Sell) for the stock. This suggests the shares may continue to lag the market in the short term. A comprehensive list of Zacks #1 Rank (Strong Buy) stocks is available for those interested.
It will be important to watch how earnings estimates change in the upcoming days. The current consensus EPS estimate is $0.41, with projected revenues of $152.32 million for the next quarter, and for the fiscal year, it is $2 on revenues of $619.34 million.
Investors should also consider that the industry outlook can substantially influence stock performance. Currently, the Medical – Generic Drugs sector ranks in the top 20% of over 250 Zacks industries. Historically, the top half of industries outperform the bottom half by more than 2 to 1.
In the same industry, Amphastar Pharmaceuticals (AMPH) has yet to release its results for the quarter ending September 2024, with an expected announcement on November 6.
The specialty pharmaceutical company is projected to report quarterly earnings of $1.03 per share, reflecting a year-over-year decrease of 10.4%. The EPS estimate for the quarter has seen a 1.3% downward revision in the past 30 days.
Amphastar’s revenue is expected to hit $195.81 million, marking an 8.5% increase compared to the previous year.
Research Chief Highlights Potential Stock Growth
Among thousands of stocks, five Zacks experts have pinpointed their favorite for substantial gains over the coming months. Director of Research Sheraz Mian has identified one stock he believes could deliver the highest upside.
This company is engaging millennial and Gen Z markets, reporting nearly $1 billion in revenue last quarter. A recent market dip may present a favorable entry point. While not all recommendations yield returns, this pick follows previous successful suggestions, like Nano-X Imaging, which surged by 129.6% in just over nine months.
Want the latest insights from Zacks Investment Research? You can currently access “5 Stocks Set to Double” for free.
Supernus Pharmaceuticals, Inc. (SUPN): Free Stock Analysis Report
Amphastar Pharmaceuticals, Inc. (AMPH): Free Stock Analysis Report
To read this article on Zacks.com, click here.
Zacks Investment Research
The views and opinions expressed herein are those of the author and do not necessarily reflect the views of Nasdaq, Inc.
